Willow GLP-1 Review (2026): Flat Pricing, Real Caveats

What Is Willow?

Willow is a cash-pay telehealth company headquartered in Austin, Texas, that focuses exclusively on compounded GLP-1 medications for weight loss. It does not offer branded Ozempic or Wegovy — only compounded semaglutide and tirzepatide made by 503A compounding pharmacies that fill individual patient prescriptions. Prescriptions are written by licensed physicians through Willow Medical of California, P.C.

The company holds LegitScript certification, which means it has been independently verified for compliance with pharmacy laws, prescription requirements, and patient safety standards. That credential matters in a market crowded with unvetted operators.

One important limitation: Willow is currently available in only 33 states. If you live outside that footprint, you cannot enroll regardless of your health profile. Check the current state list at joinwillow.com before spending time on the intake form.

How Willow Works

Signing up starts with an online intake form covering your weight history, health conditions, and current medications. A provider from Willow Medical of California, P.C. reviews your information asynchronously — there is no live video call required for most patients — and issues a prescription if you qualify.

Once approved, a 503A-licensed compounding pharmacy fills your prescription and ships it directly to your door. Willow offers compounded semaglutide as an injectable and as an oral tablet. Compounded tirzepatide is injectable only. Dose titration follows a standard escalation schedule; you work with your provider to increase your dose over time.

• Asynchronous provider visits — no scheduled video call required for most patients
• Medications shipped directly from compounding pharmacy to your home
• Dose adjustments coordinated through the patient portal
• HSA and FSA cards accepted at checkout; a letter of medical necessity is available in the portal
• No labs included — you must arrange bloodwork independently or through your primary care provider
• No insurance accepted; entirely cash-pay

Willow Pricing

Willow's flat-rate model is its most distinctive feature. Most GLP-1 telehealth companies charge more as your dose increases, which means costs climb steadily over the first year of treatment. Willow locks in the same monthly rate regardless of dose.

• Compounded semaglutide (injection or oral tablet): $299/month
• Compounded tirzepatide (injection): $399/month
• No membership fee, no visit fee, no per-dose surcharge
• No insurance accepted; HSA and FSA payments accepted

At $299 per month, compounded semaglutide from Willow annualizes to roughly $3,588 per year — a fraction of what brand-name Wegovy costs out of pocket. The tirzepatide plan runs approximately $4,788 per year. There are no hidden fees buried in the checkout flow.

Who Willow Is For

Willow suits budget-conscious patients in one of the 33 supported states who want a predictable monthly cost and do not need integrated lab work or live provider calls. It is a particularly good fit if you already have a primary care provider handling your lab monitoring and simply want access to affordable compounded GLP-1 medication.

Willow is a weaker fit if you want hands-on clinical support, insurance billing, nationwide availability, or the peace of mind of brand-name FDA-approved medications. Patients with complex metabolic conditions who need close monitoring will find the no-labs model limiting.

• Good fit: Budget-focused patients in a supported state who self-manage monitoring
• Good fit: Patients with an existing PCP who will track labs
• Good fit: HSA/FSA holders looking to maximize pre-tax health dollars
• Not a fit: Patients outside the 33 supported states
• Not a fit: Those who want live video visits or integrated lab draws
• Not a fit: Patients who prefer FDA-approved branded medications

Regulatory Landscape: What Patients Should Know

The compounded GLP-1 market is under significant regulatory pressure heading into mid-2026. The FDA resolved the semaglutide shortage in February 2025, which removed the primary legal basis for large-scale 503B compounding. In April 2026, the FDA proposed removing semaglutide, tirzepatide, and liraglutide from the 503B bulk substances list entirely, targeting high-volume compounder pharmacies.

Willow uses 503A compounding pharmacies, which fill individual patient prescriptions rather than producing bulk stock. The FDA's April 2026 proposal specifically targeted 503B bulk compounders, and 503A pharmacies have somewhat more legal latitude — but they are not immune. The FDA has signaled that 503A pharmacies must document patient-specific medical need for compounded formulations.

Separately, the National Advertising Division referred Willow to state attorneys general in December 2025 after finding the company could not substantiate weight-loss claims by applying brand-name semaglutide clinical data to its compounded formulations. No enforcement action has been publicly reported as of June 2026, but the referral is worth noting.

Verdict

Willow delivers on its core promise: genuinely flat-rate pricing on compounded GLP-1 medications, with no dose-based fee creep. The LegitScript certification and Willow Medical of California prescribing structure add meaningful credibility. For cost-conscious patients in a supported state who already have a healthcare provider managing their lab work, Willow is one of the more transparent and affordable options in the compounded GLP-1 space.

The caveats are real. Geographic coverage of 33 states excludes a large chunk of the country. No labs are included, which puts monitoring responsibility entirely on the patient. The regulatory environment for compounded semaglutide and tirzepatide is evolving quickly, and any major FDA enforcement action could disrupt service. Go in with eyes open, confirm your state is covered, and make sure your primary care provider is on board with your monitoring plan.